Diet supplement CoQ10 delays brain atrophy in aged transgenic mice with mutations in the amyloid precursor protein: An in vivo volume MRI study

BioFactors

Volumn 32, Issue 1-4, 2008, Pages 169-178

  Li, Geng ^a   Jack, Clifford R ^b   Yang, Xi Fei ^a   Yang, Edward S ^a  

^a HONG KONG APPLIED SCIENCE AND TECHNOLOGY RESEARCH INSTITUTE   (Hong Kong)

^b MAYO CLINIC   (United States)

Author keywords

Alzheimer's disease; Antioxidant; APP PS1 double transgenic mice; Hemispheric volume; Hippocampal volume

Indexed keywords

AMYLOID PRECURSOR PROTEIN; PRESENILIN 1; UBIDECARENONE; ANTIOXIDANT; DRUG DERIVATIVE; SCAVENGER; SERUM AMYLOID A; UBIQUINONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BRAIN ATROPHY; BRAIN SIZE; CONFERENCE PAPER; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG TISSUE LEVEL; FEMALE; GENOTYPE; HEMISPHERE; HIPPOCAMPUS; MALE; MOUSE; MUTATION; NEUROPROTECTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TRANSGENIC MOUSE; AGING; ANIMAL; ANIMAL DISEASE; ARTICLE; ATROPHY; BRAIN; COGNITIVE DEFECT; DRUG EFFECT; GENETICS; HISTOLOGY; PATHOLOGY; PHYSIOLOGY;

MUS; MUS MUSCULUS;

AGING; ANIMALS; ANTIOXIDANTS; ATROPHY; BRAIN; CEREBRUM; COGNITION DISORDERS; FEMALE; FREE RADICAL SCAVENGERS; HIPPOCAMPUS; MAGNETIC RESONANCE IMAGING; MALE; MICE; MICE, TRANSGENIC; PRESENILIN-1; SERUM AMYLOID A PROTEIN; UBIQUINONE;

EID: 58149373850     PISSN: 09516433     EISSN: None     Source Type: Journal    
DOI: 10.1002/biof.5520320120     Document Type: Conference Paper

References (57)

1. J. Apelt, M. Bigl, P. Wunderlich and R. Schliebs, Aging-related increase in oxidative stress correlates with developmental pattern of beta-secretase activity and beta-amyloid plaque formation in transgenic Tg2576 mice with Alzheimer-like pathology, Int J Dev Neurosci 22 (2004), 475-484.
2. F.C. Barone, R.K. Clark, G. Feuerstein, R.E. Lenkinski and S.K. Sarkar, Quantitative comparison of magnetic resonance imaging (MRI) and histologic analyses of focal ischemic damage in the rat, Brain Res Bull 26 (1991), 285-291.
3. T.A. Bayer, S. Schafer, H. Breyhan, O. Wirths, C. Treiber and G.A. Multhaup, vicious circle: role of oxidative stress, intraneuronal Abeta and Cu in Alzheimer's disease, Clin Neuropathol 25 (2006), 163-171.
4. C. Behl and B. Moosmann, Antioxidant neuroprotection in Alzheimer's disease as preventive and therapeutic approach, Free Radic Biol Med 33 (2002), 182-191.
5. G. Benzi and A. Moretti, Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging 16 (1995), 661-674.
6. D. Boyd-Kimball, R. Sultana, H. Mohmmad-Abdul and D.A. Butterfield, Neurotoxicity and oxidative stress in D1M-substituted Alzheimer's A beta (1-42): relevance to N-terminal methionine chemistry in small model peptides, Peptides 26 (2005), 665-673.
7. D.A. Butterfield, Amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity: implications for neurodegeneration in Alzheimer's disease brain, A review, Free Radic Res 36 (2002), 1307-1313.
8. D.A. Butterfield and D. Boyd-Kimball, Amyloid beta-peptide (1-42) contributes to the oxidative stress and neurodegeneration found in Alzheimer disease brain, Brain Pathol 14 (2004), 426-432.
9. D.A. Butterfield, A. Castegna, C.M. Lauderback and J. Drake, Evidence that amyloid beta-peptide-induced lipid peroxidation and its sequelae in Alzheimer's disease brain contribute to neuronal death, Neurobiol Aging 23 (2002), 655-664.
10. D.A. Butterfield, J. Drake, C. Pocernich and A. Castegna, Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid beta-peptide, Trends Mol Med 7 (2001), 548-554.
11. D.A. Butterfield, M. Perluigi and R. Sultana, Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics, Eur J Pharmacol 545 (2006), 39-50.
12. T.M. Buttke and P.A. Sandstrom, Oxidative stress as a mediator of apoptosis, Immunol Today 15 (1994), 7-10.
13. J.T. Coyle and P. Puttfarcken, Oxidative stress, glutamate, and neurodegenerative disorders, Science 262 (1993), 689-695.
14. J.D. D'Amore, S.T. Kajdasz, M.E. McLellan, B.J. Bacskai, E.A. Stern and B.T. Hyman, In vivo multiphoton imaging of a transgenic mouse model of Alzheimer disease reveals marked thioflavine-S-associated alterations in neurite trajectories, J Neuropathol Exp Neurol 62 (2003), 137-145.
15. F. de Bustos, J.A. Molina, F.J. Jimenez-Jimenez, A. Garcia-Redondo, C. Gomez-Escalonilla, J. Porta-Etessam, A. Berbel, M. Zurdo, B. Barcenilla, G. Parrilla, R. Enriquez-de-Salamanca and J. Arenas, Serum levels of coenzyme Q10 in patients with Alzheimer's disease, J Neural Transm 107 (2000), 233-239.
16. R.S. Doody, J.C. Stevens, C. Beck, R.M. Dubinsky, J.A. Kaye, L. Gwyther, R.C. Mohs, L.J. Thal, P.J. Whitehouse, S.T. DeKosky and J.L. Cummings, Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology 56 (2001), 1154-1166.
17. J. El Khoury, S.E. Hickman, C.A. Thomas, J.D. Loike and S.C. Silverstein, Microglia, scavenger receptors, and the pathogenesis of Alzheimer's disease, Neurobiol Aging 19 (1998), S81-84.
18. L. Ernster and G. Dallner, Biochemical, physiological and medical aspects of ubiquinone function, Biochim Biophys Acta 1271 (1995), 195-204.
19. 10 and remacemide in transgenic mouse models of Huntington's disease, J Neurosci 22 (2002), 1592-1599.
20. B. Frei, M.C. Kim, B.N. Ames, Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations, Proc Natl Acad Sci USA 87 (1990), 4879-4883.
21. M. Garcia-Alloza, S.A. Dodwell, M. Meyer-Luehmann, B.T. Hyman and B.J. Bacskai, Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model, J Neuropathol Exp Neurol 65 (2006), 1082-1089.
22. M. Grundman and P. Delaney, Antioxidant strategies for Alzheimer's disease, Proc Nutr Soc 61 (2002), 191-202.
23. B.G. Halliwell, JMC Free radicals in biology and medicine: Oxford: Clarendon Press, 1989.
24. X. Huang, C.S. Atwood, M.A. Hartshorn, G. Multhaup, L.E. Goldstein, R.C. Scarpa, M.P. Cuajungco, D.N. Gray, J. Lim, R.D. Moir, R.E. Tanzi and A.I. Bush, The A beta peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction, Biochemistry 38 (1999), 7609-7616.
25. T. Jabs, Reactive oxygen intermediates as mediators of programmed cell death in plants and animals, Biochem Pharmacol 57 (1999), 231-245.
26. R. Katzman and J.E. Jackson, Alzheimer disease: basic and clinical advances. J Am Geriatr Soc 39 (1991), 516-525.
27. U. Keil, A. Bonert, C.A. Marques, I. Scherping, J. Weyermann, J.B. Strosznajder, F. Muller-Spahn, C. Haass, C. Czech, L. Pradier, W.E. Muller and A. Eckert, Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis, J Biol Chem 279 (2004), 50310-50320.
28. U. Keil, A. Bonert, C.A. Marques, J.B. Strosznajder, F. Muller-Spahn, W.E. Muller and A. Eckert, Elevated nitric oxide production mediates beta-amyloid-induced mitochondria failure, Pol J Pharmacol 56 (2004), 631-634.
29. D.S. Knopman, S.T. DeKosky, J.L. Cummings, H. Chui, J. Corey-Bloom, N. Relkin, G.W. Small, B. Miller and J.C. Stevens, Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology 56 (2001), 1143-1153.
30. V.Z. Lankin, A.K. Tikhaze, V.V. Kukharchuk, G.G. Konovalova, O.I. Pisarenko, A.I. Kaminnyi, K.B. Shumaev and Y.N. Belenkov, Antioxidants decreases the intensification of low density lipoprotein in vivo peroxidation during therapy with statins, Mol Cell Biochem 249 (2003), 129-140.
31. 10 on ischemic hemisphere in aged mice with mutations in the amyloid precursor protein, Neurobiol Aging 2006.
32. 10 protects SHSY5Y neuronal cells from beta amyloid toxicity and oxygen-glucose deprivation by inhibiting the opening of the mitochondrial permeability transition pore, Biofactors 25 (2005), 97-107.
33. M.A. Lovell and W.R. Markesbery, Amyloid beta peptide, 4-hydroxynonenal and apoptosis, Curr Alzheimer Res 3 (2006), 359-364.
34. W.R. Markesbery and M.A. Lovell, DNA oxidation in Alzheimer's disease, Antioxid Redox Signal 8 (2006), 2039-2045.
35. Y. Matsuoka, M. Picciano, J. La Francois and K. Duff, Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease, Neuroscience 104 (2001), 609-613.
36. 10 administration increases brain mitochondrial concentrations and exerts neuroprotective effects, Proc Natl Acad Sci USA 95 (1998), 8892-8897.
37. M.E. McLellan, S.T. Kajdasz, B.T. Hyman and B.J. Bacskai, In vivo imaging of reactive oxygen species specifically associated with thioflavine S-positive amyloid plaques by multiphoton microscopy, J Neurosci 23 (2003), 2212-2217.
38. H. Mohmmad Abdul, R. Sultana, J.N. Keller, D.K. St Clair, W.R. Markesbery and D.A. Butterfield, Mutations in amyloid precursor protein and presenilin-1 genes increase the basal oxidative stress in murine neuronal cells and lead to increased sensitivity to oxidative stress mediated by amyloid beta-peptide (1-42), HO and kainic acid: implications for Alzheimer's disease, J Neurochem 96 (2006), 1322-1335.
39. H. Mohmmad Abdul, G.L. Wenk, H. Gramling, B. Hauss-Wegrzynia and D.A. Butterfield, APP and PS-1 mutations induce brain oxidative stress independent of dietary cholesterol: implications for Alzheimer's disease, Neurosci Lett 368 (2004), 148-150.
40. National Institutes of Health, National Institute on Aging Progress report on Alzheimer's, Disease, NIH Pub, (1999), No. 99-4664.
41. 10) on superoxide dismutase activity in ET-1 and ET-3 experimental models of cerebral ischemia in the rat, Folia Neuropathol 37 (1999), 247-251.
42. T. Ozben, Free radicals, oxidative stress and antioxidants, Pathological and physiological significance, New York: Plenum Press, 1998.
43. R.C. Petersen, J.C. Stevens, M. Ganguli, E.G. Tangalos, J.L. Cummings and S.T. DeKosky, Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review), Report of the Quality Standards Subcommittee of the American Academy of Neurology, Neurology 56 (2001), 1133-1142.
44. A.H. Schapira and H. Reichmann, Electron transport chain defects in Alzheimer's disease, Neurology 45 (1995), 599-600.
45. K. Schuessel, S. Schafer, T.A. Bayer, C. Czech, L. Pradier, F. Muller-Spahn, W.E. Muller and A. Eckert, Impaired Cu/Zn-SOD activity contributes to increased oxidative damage in APP transgenic mice, Neurobiol Dis 18 (2005), 89-99.
46. 10 in patients with Parkinson's disease, Exp Neurol 188 (2004), 491-494.
47. C.W. Shults, R. Haas, D. Oakes, K. Kieburtz, S. Plumb, I. Shoulson, M.F. Beal, J. Juncos and J. Nutt, Measuring the effects of therapy in Parkinson disease, Jama 291 (2004), 2430-2431, author reply 1.
48. 10 in the etiology and treatment of Parkinson's disease, Biofactor 9 (1999), 267-272.
49. 10 levels correlate with the activities of complexes I and II/III in mitochondria from parkinsonian and nonparkinsonian subjects, Ann Neurol 42 (1997), 261-264.
50. 10 in early Parkinson disease: evidence of slowing of the functional decline, Arch Neurol 59 (2002), 1541-1550.
51. 10 on risk of atherosclerosis in patients with recent myocardial infarction, Mol Cell Biochem 246 (2003), 75-82.
52. R. Sultana, D. Boyd-Kimball, H.F. Poon, J. Cai, W.M. Pierce, J.B. Klein, M. Merchant, W.R. Markesbery and D.A. Butterfield, Redox proteomics identification of oxidized proteins in Alzheimer's disease hippocampus and cerebellum: an approach to understand pathological and biochemical alterations in AD, Neurobiol Aging 27 (2006), 1564-1576.
53. R. Sultana, M. Perluigi and D.A. Butterfield, Protein oxidation and lipid peroxidation in brain of subjects with Alzheimer's disease: insights into mechanism of neurodegeneration from redox proteomics, Antioxid Redox Signal 8 (2006), 2021-2037.
54. B. Urbanc, L. Cruz, R. Le, J. Sanders, K.H. Ashe, K. Duff, H.E. Stanley, M.C. Irizarry and B.T. Hyman, Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease, Proc Natl Acad Sci USA 99 (2002), 13990-13995.
55. D.M. Walsh and D.J. Selkoe, Oligomers on the brain: the emerging role of soluble protein aggregates in neurodegeneration, Protein Pept Lett 11 (2004), 213-228.
56. J. Wang, W.R. Markesbery and M.A. Lovell, Increased oxidative damage in nuclear and mitochondrial DNA in mild cognitive impairment, J Neurochem 96 (2006), 825-832.
57. D.S. Warner, H. Sheng and I. Batinic-Haberle, Oxidants, antioxidants and the ischemic brain, J Exp Biol 207 (2004), 3221-3331.